Clinical Observation of Qishen Yiqi Dropping Pills Combined with new Oral Anticoagulants in the Intervention of Patients with High-risk Non-valvular Atrial Fibrillation
Objective: To observe the clinical efficacy and safety of Qishen Yiqi Dropping Pills combined with low-dose rivaroxaban in the treatment of high-risk patients with non-valvular atrial fibrillation (NVAF). Methods: Using the random number table method, 60 patients with high-risk non-valvular atrial fibrillation who met the criteria were randomly divided into a control group and a treatment group, with 30 cases in each group. The control group was given 10 mg rivaroxaban qd, and the treatment group was given 10 mg rivaroxaban qd. Basically, combined with 1 bag of Qishen Yiqi Dropping Pills, tid; observed the platelet (PLT), D-dimer (D-D), activated partial prothrombin time (APTT), plasma prothrombin time ( PT), quality of life score, TCM symptom score, EHRA atrial fibrillation symptom score, atrial fibrillation burden, and the incidence of embolic events and bleeding events. Results: After treatment, the PLT, D-D, TCM symptom scores, atrial fibrillation burden, and EHRA atrial fibrillation symptom scores of the two groups of pa-tients all decreased (P<0.05), and the quality of life scores increased (P<0.05). The difference was statistically signifi-cant, and after treatment The improvement degree of the above indicators in the treatment group was better than that in the control group (P<0.05); APTT and PT were both longer than before treatment (P<0.05), and the difference was statistically significant; but compared with the control group, the PT and APTT were not longer in the treatment group. Obviously, there was no statistical significance (P>0.05); there was no significant difference in embolic events and bleeding events between the two groups after treatment (P>0.05), which was not statistically significant. Conclusion: Qishen Yiqi Dropping Pills combined with low-dose rivaroxaban has definite clinical efficacy in the treatment of high-risk non-valvular atrial fibrillation patients, can effectively prevent stroke events, improve patients' quality of life, and is highly safe.
万方数据
维普
